<DOC>
	<DOCNO>NCT02428595</DOCNO>
	<brief_summary>Multi-center , prospective , within-subject control , open label clinical trial evaluate durability safety effectiveness Eclipse™ System 3 12 month use .</brief_summary>
	<brief_title>A Clinical Evaluation Eclipse™ System , Vaginal Bowel Control ( VBC ) Therapy Fecal Incontinence Women</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>Abbreviated History FI least 6 month Subject willing able give write informed consent participate study Subject read , write communicate fluently English Subject willing able comply visit schedule Subject able physically manage insertion removal Insert Abbreviated Vaginal childbirth within last 18 month Currently pregnant plan pregnancy study period Acute infection genitourinary injury would impact comfortable device use Current treatment FI medical management Removal diversion portion bowel Recent urogenital colorectal surgery Chronic abdominal pain absence diarrhea Chronic ( &gt; 6 mo ) rectal , anal pelvic pain Chronic watery diarrhea , unmanageable drug diet Inflammatory Bowel Disease ( IBD ) Chron 's Ulcerative Colitis Rectal prolapse ( mucosal full thickness ) Grade III IV hemorrhoid Pelvic organ prolapse beyond plane hymen Concurrent use intravaginal pessary device Anal pelvic malignancy within last 5 year History pelvic irradiation cancer Other significant medical lifestyle factor could confound interpretation primary endpoint increase subject risk</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>